Displaying Results 46 - 48 of 48
Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC describes the use of serum tumor markers in various types of cancer, and the lack of a useful serum tumor marker in lung cancer.
Dr. Ed Kim from the Levine Cancer Institute reviews the potential advantages and current limitations of blood-based testing for molecular markers using circulating tumor cells and circulating tumor DNA in identifying clinically important mutations.
Dr. Jack West, medical oncologist/lung cancer specialist, describes special management considerations for indolent lung cancers that may not require treatment or are at risk for “over-treatment.”
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.